MUSTANG BIO, INC. Operating Expenses
MUSTANG BIO, INC. (MBIO) reported Operating Expenses of $1.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- MUSTANG BIO, INC. operating expenses for the quarter ending 2026-06-30 was $1.17M, a 32.20% increase year-over-year.
- MUSTANG BIO, INC. operating expenses for the quarter ending 2026-03-31 was $1.06M, a 318.18% increase year-over-year.
- MUSTANG BIO, INC. operating expenses for the quarter ending 2025-12-31 was $670.00K, a 34.12% decline year-over-year.
- MUSTANG BIO, INC. operating expenses for the quarter ending 2025-09-30 was $624.00K, a 57.17% decline year-over-year.
- MUSTANG BIO, INC. operating expenses for fiscal 2025 was $2.43M, a 85.03% decline from fiscal 2024.
- MUSTANG BIO, INC. operating expenses for fiscal 2024 was $16.25M, a 67.02% decline from fiscal 2023.
- MUSTANG BIO, INC. operating expenses for fiscal 2023 was $49.26M, a 35.32% decline from fiscal 2022.
- MUSTANG BIO, INC. operating expenses for fiscal 2022 was $76.16M, a 14.14% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 7 month | Operating Expenses 9 month | Operating Expenses 10 month | Operating Expenses 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.17M 10-Q · filed 2026-08-05 | $2.23M 10-Q · filed 2026-08-05 | $2.90M derived: sum of 3 quarters · filed 2026-08-05 | $3.52M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $1.06M 10-Q · filed 2026-05-05 | $1.73M derived: sum of 2 quarters · filed 2026-05-05 | $2.35M derived: sum of 3 quarters · filed 2026-05-05 | $3.24M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $670.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.29M derived: sum of 2 quarters · filed 2026-03-19 | $2.18M derived: sum of 3 quarters · filed 2026-08-05 | $2.43M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $624.00K 10-Q · filed 2025-11-07 | $1.51M derived: sum of 2 quarters · filed 2026-08-05 | $1.76M 10-Q · filed 2025-11-07 | $2.78M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $885.00K 10-Q · filed 2026-08-05 | $1.14M 10-Q · filed 2026-08-05 | $2.15M derived: sum of 3 quarters · filed 2026-08-05 | $3.61M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $253.00K 10-Q · filed 2026-05-05 | $1.27M derived: sum of 2 quarters · filed 2026-05-05 | $2.73M derived: sum of 3 quarters · filed 2026-05-05 | $11.27M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.47M derived: sum of 2 quarters · filed 2026-03-19 | $11.01M derived: sum of 3 quarters · filed 2026-03-19 | $16.25M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $1.46M 10-Q · filed 2025-11-07 | $10.00M derived: sum of 2 quarters · filed 2025-11-07 | $15.23M 10-Q · filed 2025-11-07 | $23.97M derived: sum of 4 quarters · filed 2025-11-07 | |||
| 2024-06-30 | $8.54M 10-Q · filed 2025-08-08 | $13.77M 10-Q · filed 2025-08-08 | $22.51M derived: sum of 3 quarters · filed 2025-08-08 | $32.82M derived: sum of 4 quarters · filed 2025-08-08 | |||
| 2024-03-31 | $5.23M 10-Q · filed 2025-05-14 | $13.97M derived: sum of 2 quarters · filed 2025-05-14 | $24.28M derived: sum of 3 quarters · filed 2025-05-14 | $38.17M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $8.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $19.05M derived: sum of 2 quarters · filed 2025-03-28 | $32.94M derived: sum of 3 quarters · filed 2025-03-28 | $49.26M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | $10.31M 10-Q · filed 2024-11-08 | $24.20M derived: sum of 2 quarters · filed 2024-11-08 | $40.52M 10-Q · filed 2024-11-08 | $59.95M derived: sum of 4 quarters · filed 2024-11-08 | |||
| 2023-06-30 | $13.89M 10-Q · filed 2024-08-13 | $30.21M 10-Q · filed 2024-08-13 | $49.64M derived: sum of 3 quarters · filed 2024-08-13 | $68.49M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $16.32M 10-Q · filed 2024-05-15 | $35.75M derived: sum of 2 quarters · filed 2024-05-15 | $54.60M derived: sum of 3 quarters · filed 2024-05-15 | $72.84M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $19.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $38.28M derived: sum of 2 quarters · filed 2024-03-11 | $56.52M derived: sum of 3 quarters · filed 2024-03-11 | $76.16M 10-K · filed 2024-03-11 | |||
| 2022-09-30 | $18.85M 10-Q · filed 2023-11-14 | $37.09M derived: sum of 2 quarters · filed 2023-11-14 | $56.73M 10-Q · filed 2023-11-14 | $76.85M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $18.24M 10-Q · filed 2023-08-14 | $37.88M 10-Q · filed 2023-08-14 | $58.00M derived: sum of 3 quarters · filed 2023-08-14 | $75.08M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | $19.64M 10-Q · filed 2023-05-12 | $39.76M derived: sum of 2 quarters · filed 2023-05-12 | $56.83M derived: sum of 3 quarters · filed 2023-05-12 | $71.27M derived: sum of 4 quarters · filed 2023-05-12 | |||
| 2021-12-31 | $20.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $37.20M derived: sum of 2 quarters · filed 2023-03-30 | $51.64M derived: sum of 3 quarters · filed 2023-03-30 | $66.72M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $17.08M 10-Q · filed 2022-11-14 | $31.52M derived: sum of 2 quarters · filed 2022-11-14 | $46.60M 10-Q · filed 2022-11-14 | $67.34M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $14.44M 10-Q · filed 2022-08-11 | $29.53M 10-Q · filed 2022-08-11 | $50.27M derived: sum of 3 quarters · filed 2022-08-11 | $60.69M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $15.09M 10-Q · filed 2022-05-12 | $35.83M derived: sum of 2 quarters · filed 2022-05-12 | $46.25M derived: sum of 3 quarters · filed 2022-05-12 | $60.37M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $20.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $31.16M derived: sum of 2 quarters · filed 2022-03-23 | $45.29M derived: sum of 3 quarters · filed 2022-03-23 | $56.81M 10-K · filed 2022-03-23 | |||
| 2020-09-30 | $10.43M 10-Q · filed 2021-11-12 | $24.55M derived: sum of 2 quarters · filed 2021-11-12 | $36.07M 10-Q · filed 2021-11-12 | $51.99M derived: sum of 4 quarters · filed 2021-11-12 | |||
| 2020-06-30 | $14.12M 10-Q · filed 2021-08-16 | $25.64M 10-Q · filed 2021-08-16 | $41.56M derived: sum of 3 quarters · filed 2021-08-16 | $51.56M derived: sum of 4 quarters · filed 2021-08-16 | |||
| 2020-03-31 | $11.52M 10-Q · filed 2021-05-14 | $27.44M derived: sum of 2 quarters · filed 2021-05-14 | $37.44M derived: sum of 3 quarters · filed 2021-05-14 | $47.65M derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2019-12-31 | $15.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $25.92M derived: sum of 2 quarters · filed 2021-03-24 | $36.13M derived: sum of 3 quarters · filed 2021-03-24 | $45.88M 10-K · filed 2021-03-24 | |||
| 2019-09-30 | $10.00M 10-Q · filed 2020-11-06 | $20.21M derived: sum of 2 quarters · filed 2020-11-06 | $29.96M 10-Q · filed 2020-11-06 | $41.81M derived: sum of 4 quarters · filed 2020-11-06 | |||
| 2019-06-30 | $10.21M 10-Q · filed 2020-08-10 | $19.97M 10-Q · filed 2020-08-10 | $31.82M derived: sum of 3 quarters · filed 2020-08-10 | $39.47M derived: sum of 4 quarters · filed 2020-08-10 | |||
| 2019-03-31 | $9.75M 10-Q · filed 2020-05-11 | $21.60M derived: sum of 2 quarters · filed 2020-05-11 | $29.26M derived: sum of 3 quarters · filed 2020-05-11 | $34.50M derived: sum of 4 quarters · filed 2020-05-11 | |||
| 2018-12-31 | $11.85M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $19.51M derived: sum of 2 quarters · filed 2020-03-16 | $24.75M derived: sum of 3 quarters · filed 2020-03-16 | $31.22M 10-K · filed 2020-03-16 | |||
| 2018-09-30 | $7.66M 10-Q · filed 2019-11-12 | $12.90M derived: sum of 2 quarters · filed 2019-11-12 | $19.37M 10-Q · filed 2019-11-12 | $35.05M derived: sum of 4 quarters · filed 2019-11-12 | |||
| 2018-06-30 | $5.24M 10-Q · filed 2019-08-09 | $11.72M 10-Q · filed 2019-08-09 | $27.40M derived: sum of 3 quarters · filed 2019-08-09 | $34.48M derived: sum of 4 quarters · filed 2019-08-09 | |||
| 2018-03-31 | $6.43M 10-Q · filed 2019-05-10 | $6.48M 10-Q · filed 2018-05-14 | $22.16M derived: sum of 2 quarters · filed 2019-05-10 | $29.24M derived: sum of 3 quarters · filed 2019-05-10 | $34.91M derived: sum of 4 quarters · filed 2019-05-10 | ||
| 2017-12-31 | $15.73M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $22.81M derived: sum of 2 quarters · filed 2019-03-18 | $28.48M derived: sum of 3 quarters · filed 2019-03-18 | $31.79M 10-K · filed 2019-03-18 | |||
| 2017-09-30 | $7.08M 10-Q · filed 2018-11-13 | $12.75M derived: sum of 2 quarters · filed 2018-11-13 | $16.06M 10-Q · filed 2018-11-13 | $23.89M derived: sum of 4 quarters · filed 2018-11-13 | |||
| 2017-06-30 | $5.67M 10-Q · filed 2018-08-13 | $8.97M 10-Q · filed 2018-08-13 | $16.80M derived: sum of 3 quarters · filed 2018-08-13 | $18.47M derived: sum of 4 quarters · filed 2018-08-13 | |||
| 2017-03-31 | $3.31M 10-Q · filed 2018-05-14 | $11.14M derived: sum of 2 quarters · filed 2018-05-14 | $12.81M derived: sum of 3 quarters · filed 2018-05-14 | $13.85M derived: sum of 4 quarters · filed 2018-05-14 | |||
| 2016-12-31 | $7.83M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $9.50M derived: sum of 2 quarters · filed 2018-03-29 | $10.54M derived: sum of 3 quarters · filed 2018-03-29 | $11.36M 10-K · filed 2018-03-29 | |||
| 2016-09-30 | $1.67M 10-Q · filed 2017-11-14 | $2.71M derived: sum of 2 quarters · filed 2017-11-14 | $3.53M 10-Q · filed 2017-11-14 | ||||
| 2016-06-30 | $1.04M 10-Q · filed 2017-08-14 | $1.86M 10-Q · filed 2017-08-14 | |||||
| 2015-12-31 | $4.30M 10-K · filed 2018-03-29 | ||||||
| 2015-09-30 | $658.00K 10-Q · filed 2016-11-14 | $3.46M 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |